Literature DB >> 7667201

Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro.

N Pennanen1, S Lapinjoki, A Urtti, J Mönkkönen.   

Abstract

PURPOSE: In order to evaluate the possible antiinflammatory action of bisphosphonates, the effect of the drugs on the secretion of proinflammatory cytokines (IL-1 beta, IL-6 and TNF alpha) from macrophages was studied. Liposomes or high concentration of extracellular calcium was used to enhance the intracellular delivery of bisphosphonates.
METHODS: RAW 264 cells were used as macrophage model, and they were induced with lipopolysaccharide to produce the cytokines. The cytokine concentrations in the culture supernatants were measured with time-resolved fluoroimmunoassay.
RESULTS: As a free drug, clodronate and pamidronate, but not etidronate, inhibited LPS-stimulated secretion of the cytokines from macrophage-like RAW 264 cells. Low concentrations of pamidronate, however, induced the IL-6 secretion, and the cytokine inhibitory action at the higher concentrations of pamidronate was attributed to cytotoxicity of the compound. The cytokine induction or toxic effects were not observed with clodronate or etidronate. When the drugs were encapsulated in negatively charged unilamellar liposomes, the inhibitory potency of both clodronate and etidronate enhanced by a factor of 10-20, while that of pamidronate was not increased. The complex formation of bisphosphonates with extracellular calcium, although enhancing the uptake of the compounds by macrophages, did not considerably increase their cytokine inhibitory potency.
CONCLUSIONS: Bisphosphonates have inhibitory action on cytokine secretion by macrophages. The non-cytotoxic cytokine inhibition by liposome encapsulated clodronate could be beneficial in local inflammatory diseases, where the inflammation is sustained by the excessive amounts of inflammatory cytokines produced by activated macrophages.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7667201     DOI: 10.1023/a:1016281608773

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  26 in total

1.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

Review 2.  Anti-inflammatory actions of steroids: molecular mechanisms.

Authors:  P J Barnes; I Adcock
Journal:  Trends Pharmacol Sci       Date:  1993-12       Impact factor: 14.819

Review 3.  How important are T cells in chronic rheumatoid synovitis?

Authors:  G S Firestein; N J Zvaifler
Journal:  Arthritis Rheum       Date:  1990-06

Review 4.  Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF).

Authors:  S Akira; T Hirano; T Taga; T Kishimoto
Journal:  FASEB J       Date:  1990-08       Impact factor: 5.191

5.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.

Authors:  M B Hansen; S E Nielsen; K Berg
Journal:  J Immunol Methods       Date:  1989-05-12       Impact factor: 2.303

6.  Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineage.

Authors:  M G Cecchini; H Fleisch
Journal:  J Bone Miner Res       Date:  1990-10       Impact factor: 6.741

7.  Effect of bisphosphonates on production of interleukin 1-like activity by macrophages and its effect on rabbit chondrocytes.

Authors:  V Evêquoz; U Trechsel; H Fleisch
Journal:  Bone       Date:  1985       Impact factor: 4.398

8.  Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro.

Authors:  J Mönkkönen; M Taskinen; S O Auriola; A Urtti
Journal:  J Drug Target       Date:  1994       Impact factor: 5.121

9.  Demonstration of novel anti-arthritic and anti-inflammatory effects of diphosphonates.

Authors:  C J Dunn; L A Galinet; H Wu; R A Nugent; S T Schlachter; N D Staite; D G Aspar; G A Elliott; N A Essani; N A Rohloff
Journal:  J Pharmacol Exp Ther       Date:  1993-09       Impact factor: 4.030

10.  Augmentation and suppression of release of tumor necrosis factor from macrophages by negatively charged phospholipids.

Authors:  S Yui; M Yamazaki
Journal:  Jpn J Cancer Res       Date:  1991-09
View more
  48 in total

1.  Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !?

Authors:  J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

2.  Novel macrophage polarization model: from gene expression to identification of new anti-inflammatory molecules.

Authors:  Gloria Lopez-Castejón; Alberto Baroja-Mazo; Pablo Pelegrín
Journal:  Cell Mol Life Sci       Date:  2010-12-28       Impact factor: 9.261

Review 3.  Nanotherapeutic approaches for the treatment of rheumatoid arthritis.

Authors:  Christine T N Pham
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-08-11

4.  Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women MESA (The Multi-Ethnic Study of Atherosclerosis).

Authors:  Sammy Elmariah; Joseph A C Delaney; Kevin D O'Brien; Matthew J Budoff; Jens Vogel-Claussen; Valentin Fuster; Richard A Kronmal; Jonathan L Halperin
Journal:  J Am Coll Cardiol       Date:  2010-11-16       Impact factor: 24.094

5.  Myocardial infarction risk among patients with fractures receiving bisphosphonates.

Authors:  Cory B Pittman; Lisa A Davis; Angelique L Zeringue; Liron Caplan; Kent R Wehmeier; Jeffrey F Scherrer; Hong Xian; Francesca E Cunningham; Jay R McDonald; Alexis Arnold; Seth A Eisen
Journal:  Mayo Clin Proc       Date:  2014-01       Impact factor: 7.616

6.  Bisphosphonates Inhibit Pain, Bone Loss, and Inflammation in a Rat Tibia Fracture Model of Complex Regional Pain Syndrome.

Authors:  Liping Wang; Tian-Zhi Guo; Saiyun Hou; Tzuping Wei; Wen-Wu Li; Xiaoyou Shi; J David Clark; Wade S Kingery
Journal:  Anesth Analg       Date:  2016-10       Impact factor: 5.108

7.  The cellular uptake and metabolism of clodronate in RAW 264 macrophages.

Authors:  H Mönkkönen; M J Rogers; N Makkonen; S Niva; S Auriola; J Mönkkönen
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

8.  Successful treatment of SAPHO syndrome with an oral bisphosphonate.

Authors:  Jiro Ichikawa; Eiichi Sato; Hirotaka Haro; Takashi Ando; Singo Maekawa; Yoshiki Hamada
Journal:  Rheumatol Int       Date:  2008-11-08       Impact factor: 2.631

Review 9.  New insights into synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome.

Authors:  Marina Magrey; Muhammad A Khan
Journal:  Curr Rheumatol Rep       Date:  2009-10       Impact factor: 4.592

10.  SAPHO Syndrome Diagnosis and Treatment: Report of Five Cases and Review of the Literature.

Authors:  Ch Matzaroglou; D Velissaris; A Karageorgos; M Marangos; E Panagiotopoulos; M Karanikolas
Journal:  Open Orthop J       Date:  2009-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.